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LETTERS
Candida dubliniensis 
Infection, Singapore
To the Editor: We read with inter-
est the letter by Marriott et al. (1)
describing the first case of Candida
dubliniensis fungemia in Australia.
We report the first two cases of C.
dubliniensis infection in Singapore.
We have been using the API 20C
AUX on all yeast isolates from blood,
sterile fluids, and tissue to screen for
C. dubliniensis since May 2000. To
our knowledge, this infection has not
been previously reported from a
Southeast Asian country. 
The first patient was a 49-year-old
woman with adult polycystic kidney
and liver disease; she had mild chronic
renal failure and a past history of
nephrotic syndrome. She was admitted
to the renal unit on May 9, 2001, for
management of ascites. A septic
workup showed leukocytosis (34.67 x
109/L) with predominance of neutro-
phils (95%). Blood culture received on
May 31 grew yeast with two slightly
different forms, one large and one
small. The isolates, investigated sepa-
rately, were germ-tube positive. The
API 20C AUX profile for the larger
isolate was 6072114 at 48 hours’ incu-
bation (96.2% certainty for C. dublin-
iensis) and 6072134 for the smaller
isolate (99.8% certainty for C. dublin-
iensis). The yeasts grew well on potato
dextrose agar at 35°C but poorly at
42°C and 45°C. In addition, electro-
phoretic karyotyping with pulsed-field
gel electrophoresis showed that both
isolates had identical patterns, with
eight chromosome fragments, one of
which was <1 megabase (Mb), indi-
cating that the two morphologically
different strains were the same karyo-
typically. The pattern obtained was in
keeping with results obtained by
Jabra-Rizk et al. (2), with C. dublin-
iensis showing a chromosome-sized
band of <1 Mb. For C. albicans, by
contrast, all bands were >1 Mb. Five
control strains—C. dubliniensis
(RCPA Microbiology QAP item
2001:2:7A), C. albicans ATCC 90028,
and three clinical strains of C.  albi-
cans—were also run together with the
two strains; the results obtained were
consistent with those of Jabra-Rizk et
al. (2). The MIC of the isolates to flu-
conazole by E-test was 0.75 µg/mL,
indicating susceptibility. Disseminated
intravascular coagulopathy due to sep-
sis from a possible ruptured liver cyst
developed in the patient. Despite
broad-spectrum antibiotics and
amphotericin B, hemodialysis, and
intensive-care support, she died 5
weeks after admission. Except for C.
dubliniensis candidemia, Candida
species isolated from the urine and
endotracheal secretions (speciation
not done), and Acinetobacter bauman-
nii  (cultured from the endotracheal
secretions and femoral catheter tip),
no other important microorganisms
were isolated. Peritoneal fluid cultures
did not yield any microorganisms.
Soon after the first case, C. dublin-
iensis was isolated from a sputum cul-
ture and bronchial alveolar lavage
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cultures from a 50-year-old Chinese
woman, who had myelodysplastic
syndrome and was hospitalized for
pneumonia. She had been previously
treated with chemotherapy and had
multiple admissions for infection. The
same phenotypic and karyotypic
methods as the first patient were used
to identify the isolate. The API 20C
AUX profile was 2152134 at 48 hours
(98.5% certainty for C. dubliniensis).
The MIC of fluconazole by E-test was
also 0.75 µg/mL. Pancytopenia devel-
oped, and the patient’s condition dete-
riorated. She died of pneumonia
despite transfusions and treatment
with broad-spectrum antibiotics and
amphotericin B. Microbiologic inves-
tigations for bacteria, tuberculosis,
pneumocystis, Legionella, and viruses
did not yield positive results except
for  Corynebacterium species in the
bronchial alveolar lavage fluid. 
Although C. dubliniensis was first
associated with oral candidiasis in
HIV-infected persons (3), several
reports now link the organism to non-
HIV patients who were immunosup-
pressed due to chemotherapy, hemato-
logic malignancy (4), and end-stage
liver disease (1). Our two patients
were not HIV positive but were immu-
nosuppressed. In vitro susceptibility
results showed that our patients should
have responded to the usual antifungal
treatment. However, they died despite
appropriate therapy.
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O157:H7 Shiga 
Toxin-Producing 
Escherichia coli 
Strains Associated 
with Sporadic 
Cases of Diarrhea in 
São Paulo, Brazil
To the Editor: Shiga toxin-pro-
ducing  Escherichia coli (STEC)
strains are associated with a spectrum
of diseases ranging from mild to
severe bloody diarrhea and complica-
tions such as hemolytic uremic syn-
drome (HUS) and thrombotic
thrombocytopenic purpura (1). Since
STEC was linked with hemorrhagic
colitis in 1982 (2), strains—particu-
larly serotype O157:H7—have been
associated with numerous outbreaks
and many sporadic cases of infections
worldwide. STEC is now a major
cause of foodborne disease, primarily
in the United States, Canada, Japan,
and Europe (1,3). Although most spo-
radic cases and outbreaks have been
reported from developed countries,
human infections associated with
STEC strains have also been described
in Latin American countries, including
Argentina and Chile (3). In Brazil,
STEC infections have been related to
sporadic cases of nonbloody diarrhea
caused by non-O157 strains (4,5);
serotype O157:H7 has not been previ-
ously isolated from human infections
in our country.
We report the characterization of
three O157:H7 strains isolated in São
Paulo State, Brazil. The first strain
was identified among a laboratory col-
lection of 2,573 E. coli strains that
were retrospectively analyzed and iso-
lated from patients with diarrhea in
São Paulo State, from 1976 through
1999, at the Central Laboratory of
Instituto Adolfo Lutz (IAL). This
strain was isolated in 1990 from an
18-year-old patient with diarrheal dis-
ease who had AIDS. The two other
O157 strains were recently isolated
from a 4-year-old girl with bloody
diarrhea and from an adult with severe
diarrhea. Both patients were admitted
to the same hospital at Campinas, São
Paulo State, in June and July 2001,
respectively. The strains, isolated by
routine diagnostic procedures on Mac-
Conkey agar plates, were presump-
tively identified as E. coli O157 by
standard methods with specific O157
antiserum. These last two strains were
confirmed as sorbitol-negative E. coli
O157 at the IAL Regional Laboratory
at Campinas and were sent to the IAL
Central Laboratory for further charac-
terization. 
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